Search research articles
Contact Us
Filters
Showing results (121-130 of 137) with videos related to
Page
of 14
Sort By:
The British Journal of Dermatology
|
September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Eric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
Journal of the American Association of Nurse Practitioners
|
September 14, 2018
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
Susan J Tofte, Kim Papp, Neil Sadick, et al.
JAMA Dermatology
|
November 2, 2022
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines
Sara Mirali, Evan Tang, Aaron M Drucker, et al.
Rheumatology and Therapy
|
October 1, 2025
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
Andrew Östör, Filip Van den Bosch, Kim Papp, et al.
Dermatology and Therapy
|
November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
April Armstrong, Carle Paul, Luis Puig, et al.
Journal of Cutaneous Medicine and Surgery
|
September 15, 2017
An Open Letter to Health Canada
Kim Papp, Lorne Albrecht, Kirk Barber, et al.
Arthritis and Rheumatism
|
March 2, 2012
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
Arthur Kavanaugh, Désirée van der Heijde, Iain B McInnes, et al.
Journal of Cutaneous Medicine and Surgery
|
March 20, 2024
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey
Erika Y Lee, Irina Turchin, An-Wen Chan, et al.
Dermatology and Therapy
|
March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Craig Leonardi, Kristian Reich, Peter Foley, et al.
Journal of the American Academy of Dermatology
|
February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 137) with videos related to
Sort By:
Page
of 14
The British Journal of Dermatology
|
September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Eric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
Journal of the American Association of Nurse Practitioners
|
September 14, 2018
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
Susan J Tofte, Kim Papp, Neil Sadick, et al.
JAMA Dermatology
|
November 2, 2022
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines
Sara Mirali, Evan Tang, Aaron M Drucker, et al.
Rheumatology and Therapy
|
October 1, 2025
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
Andrew Östör, Filip Van den Bosch, Kim Papp, et al.
Dermatology and Therapy
|
November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
April Armstrong, Carle Paul, Luis Puig, et al.
Journal of Cutaneous Medicine and Surgery
|
September 15, 2017
An Open Letter to Health Canada
Kim Papp, Lorne Albrecht, Kirk Barber, et al.
Arthritis and Rheumatism
|
March 2, 2012
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
Arthur Kavanaugh, Désirée van der Heijde, Iain B McInnes, et al.
Journal of Cutaneous Medicine and Surgery
|
March 20, 2024
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey
Erika Y Lee, Irina Turchin, An-Wen Chan, et al.
Dermatology and Therapy
|
March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Craig Leonardi, Kristian Reich, Peter Foley, et al.
Journal of the American Academy of Dermatology
|
February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Page
of 14